Spotting a potential supply issue is the first step. What happens in the weeks and months afterwards is often far more revealing.

Throughout the year, our subscriber newsletter highlights individual medicines that our team believes are worth watching. Every so often, it is useful to go back.

Several medicines highlighted earlier this year have since seen significant developments. Looking at them again provides an interesting snapshot of how quickly market conditions can change, and why early visibility matters.

Sumatriptan: six months on

We first highlighted Sumatriptan 50mg tablets to newsletter subscribers on 23 March.

At the time, pricing was still stable, but quotations had already started to drift from historic norms, an early sign rather than a settled conclusion. By August, activity had increased substantially, with 38 alerts recorded across the four weeks to 18 August, 18 of them UK-specific.

Nearly six months after our original analysis, it hasn’t eased: 26 alerts in the past 30 days, and UK risk now rated Very High, one of the highest ratings we track.

What began as something worth watching has therefore remained relevant for considerably longer than a short-term fluctuation.

Betahistine: a changing UK picture

Betahistine 16mg tablets was highlighted in the same March edition, the pattern was mostly international, with just the first few UK reports starting to appear.

By August, that had reversed. 14 alerts were recorded across the four weeks to 25 August, with 11 of those UK-specific, meaning the majority of recorded activity had shifted from the international pattern to a domestic one, exactly the trajectory the original card flagged as a possibility.

It is a useful reminder that the position surrounding an individual medicine can evolve significantly over a relatively short period, and that today’s limited activity can look quite different several months later.

Amlodipine: significant price movement

Amlodipine 5mg and 10mg tablets were highlighted on 30 March.

When we highlighted them at the end of March, the concern was fairly specific: a high-volume, low-tariff generic doesn’t have much room to absorb disruption before pricing moves. At the time, both strengths were still trading close to Drug Tariff. By August, the picture had changed.

For Amlodipine 10mg, our tracked price moved from approximately £0.32 in April to £6.68 in August, with one wholesaler quotation reaching £10.07 on 24 August, over thirty times where it started.

Amlodipine 5mg also moved substantially, from approximately £0.28 to £2.07 over the same period, with an individual quotation reaching £3.75.

Individual quotations don’t represent the whole market and should be interpreted with appropriate caution. Nevertheless, once sourcing got harder, the low starting price left little room before quotations moved well above tariff, exactly the mechanism the original card described.

Early visibility matters

There is an important distinction between identifying something worth watching and predicting a shortage.

Not every medicine we highlight will develop into a sustained supply problem, and neither alert volumes nor individual price movements establish the cause or severity of a shortage.

But these examples demonstrate why we continue to revisit medicines after they first attract our attention.

Market conditions move, sometimes quickly, and by the time a problem becomes widely visible, its story may already have been developing for some time.

For our subscribers, identifying the medicines worth watching - and following what happens next - is an ongoing part of the picture we provide each week.

Sources

iEthico newsletter analysis, March and August 2026; tracked wholesaler quotations, Drug Tariff data and recorded supply alerts, September 2025–September 2026.

Alert volumes and tracked pricing indicate market activity and do not, on their own, establish the cause or severity of a shortage.